Microbial Therapeutics Articles & Analysis
12 news found
It will also use this influx of funds to push forward research of new microbial therapeutics and development of FDA-approved live biotherapeutic products (LBP). Herb Lin, a managing partner at TPTF, first learned of Bened through his fund’s investment in Finch Therapeutics, a microbiome therapy company now listed on the NASDAQ. He ...
AgBio: Biofertilizers, microbiome engineering, bioavailability, crops (yield increase, protection, fertility, productivity, climate adaptation/change mitigation), soil treatment, and smart agriculture. BioPharma: Microbiome therapeutics, anti-microbial resistance, personalised/stratified medicine, therapeutics for gastrointestinal and ...
Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. ...
This research serves as the foundation for Axial Therapeutics’ potential new treatment, AB-2004, for managing irritability associated with ASD in children. ...
"Wacker Biotech's expertise in large-scale, high-quality microbial manufacturing is a perfect fit for production of therapeutic candidates for clinical testing from Actym's state-of-the-art STACT platform." ...
Study adds to growing evidence for how gut microbiome impacts Central Nervous System (CNS) function and behavior in mice Research offers valuable mechanistic insights for understanding the potential role of microbial metabolites in neurodevelopmental disorders Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of ...
“The data highlighted in Nature Medicine further support our novel therapeutic strategy focused on specific targets in the gut microbiome. ...
EnteroBiotix, a biopharmaceutical company developing novel highly-diverse microbial therapeutics that enhance the gut microbiome, today announced the mechanical completion of a new purpose built world-class facility at Strathclyde Business Park, Glasgow, for manufacturing and quality control of its high-diversity microbial ...
EnteroBiotix, a biopharmaceutical company developing novel high-diversity microbial therapeutics that enhance the gut microbiome and target multiple indications, today announced the final closing of its oversubscribed USD $21.5 million (UK £15.5m) Series A financing. ...
“The microbiome has progressively become an attractive target for potential therapeutics. However, one of the biggest difficulties is to determine cause-effect relationships and to design microbial therapeutics for these conditions. We are dedicated to offering a full list of microbial genomics services to accelerate the ...
“We are one step closer to bringing tailored, clinically differentiated microbial therapeutics to the market.” This comes on the heels of other operational and regulatory successes for the company, which includes the expansion of its executive team with the addition of John Martin, PhD and former CEO/Chairman of Gilead, as an executive advisor; and ...
The company has built a human-centric development platform that delivers patient screening for high-risk candidates, targeted microbial therapeutics, and biomarker discovery for responder/non-responder analytics. ...